Novo Nordisk: Addressing MASH as a liver manifestation of the metabolic disease - EASL SLD Summit 2025
View
Metabolism, Alcohol & Toxicity
5
Novo Nordisk: Addressing MASH as a liver manifestation of the metabolic disease - EASL SLD Summit 2025
View
Metabolism, Alcohol & Toxicity
5
Novo Nordisk: Addressing MASH as a liver manifestation of the metabolic disease - EASL SLD Summit 2025
View
Metabolism, Alcohol & Toxicity
5
Novo Nordisk: Addressing MASH as a liver manifestation of the metabolic disease - EASL SLD Summit 2025
View
Cirrhosis & Complications
6
Shionogi: Procedural risk of bleeding – does the management of TCP in CLD patients make a difference? A debate - The International Liver Congress™ 2019
View
Cirrhosis & Complications
6
Shionogi: Procedural risk of bleeding – does the management of TCP in CLD patients make a difference? A debate - The International Liver Congress™ 2019
View
Cirrhosis & Complications
6
Shionogi: Procedural risk of bleeding – does the management of TCP in CLD patients make a difference? A debate - The International Liver Congress™ 2019
View
Cirrhosis & Complications
6
Shionogi: Procedural risk of bleeding – does the management of TCP in CLD patients make a difference? A debate - The International Liver Congress™ 2019
View
Cirrhosis & Complications
6
Shionogi: Procedural risk of bleeding – does the management of TCP in CLD patients make a difference? A debate - The International Liver Congress™ 2019
View
Cirrhosis & Complications
6
Shionogi: Procedural risk of bleeding – does the management of TCP in CLD patients make a difference? A debate - The International Liver Congress™ 2019
View
General Hepatology
6
Alexion: My Patient Care vs Restricted Access to Medicines - The International Liver Congress™ 2019
View
General Hepatology
6
Alexion: My Patient Care vs Restricted Access to Medicines - The International Liver Congress™ 2019
